Diseases
Huntington's disease (HD) is a rare and hereditary neurodegenerative disease that causes progressive neuronal death and manifests as a deterioration of cognitive, behavioural and motor functions.
HD is not very common, affecting 4.88 people per 100,000 inhabitants¹. The disease usually appears in adulthood (between the ages of 35 and 55), although a small percentage develop symptoms before the age of 20, which is known as juvenile HD².
HD causes a combination of motor, psychiatric and cognitive symptoms, which can vary considerably between individuals4. Motor problems often include involuntary movements (chorea) and difficulties in voluntary control. Psychiatric and behavioral changes, such as depression, apathy, irritability, and anxiety, are common and may arise in the early stages of the disease5. Cognitive symptoms, especially executive dysfunction, usually appear before clear motor signs manifest6.
After its onset, the disease usually progresses over 15-20 years4, causing difficulties in behavior, thinking and movement, and eventually leading to severe disability and death.
We join forces with large companies with the purpose of providing solutions to the challenges of Barcelona
Ferrer and Prilenia Announce Start of PRECISE-HD Confirmatory Clinical Trial of Pridopidine in Huntington's Disease
First participant in Europe in the Phase 3 clinical trial "PREVAiLS" with pridopidine, in ALS
IMPAHCT celebrates its eighth edition by reinforcing the comprehensive approach to rare lung diseases
Ferrer and Prilenia Announce Inclusion of First Participant in Phase 3 Clinical Trial "PREVAiLS" with Pridopidine, in ALS
Last updated: July 2026
